|Year : 2020 | Volume
| Issue : 5 | Page : 957-959
TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma
Xin Li1, Ping Liang1, Xin Ye2
1 Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China
2 Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong Province, China
|Date of Submission||24-Jun-2020|
|Date of Decision||28-Jul-2020|
|Date of Acceptance||29-Jul-2020|
|Date of Web Publication||29-Sep-2020|
Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong Province 250014
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Li X, Liang P, Ye X. TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma. J Can Res Ther 2020;16:957-9
The incidence and mortality of primary liver cancers (PLCs) has been rising rapidly and is predicted to continue to rise in the future. In 2018, more than 800,000 new PLCs and 700,000 liver cancer-related deaths (LCRDs) were recorded worldwide, with more than 400,000 new PLCs and LCRDs occurring in China., Based on the annual projections of the World Health Organization, more than 1 million patients will die from PLCs in 2030. Most patients with hepatocellular carcinoma (HCC) are often diagnosed at an advanced stage with main vascular/bile duct invasion and distant metastases and can no longer receive radical treatment by surgery, local ablation, or liver transplantation. These patients have a dismal prognosis with rapid disease progression and short overall survival (OS). The 5-year OS ranges from 10% to 18%, and HCC is the second leading cause of overall cancer-related deaths after pancreatic cancer.,,
Advanced HCC generally comprises patients at the Barcelona Clinic Liver Cancer-stage C (BCLC-C) and BCLC-B (intermediate-stage) with disease progression after transarterial chemoembolization (TACE) therapies; even patients with BCLC-0 and A stages experience disease progression on curative treatments, and BCLC clinical staging is endorsed in clinical practice guidelines and is a widely accepted benchmark for clinical trial design.,, The classic drug sorafenib was approved by the Food and Drug Administration in 2007 as the first-line treatment for advanced HCC, which opened the door to molecular-targeted therapies for HCC (median OS of 6.5 months and 6-month OS rate of 53.3%). Although lenvatinib was recommended as a first-line treatment for advanced HCC in 2018, its clinical efficacy was not superior to that of sorafenib (median OS duration of 13.6 months vs. 12.3 months)., As a result, regorafenib, cabozantinib, and apatinib were listed as effective options for second-line treatments, but the OS was improved unsatisfactorily.,, Currently, tyrosine kinase inhibitors (TKIs), such as sorafenib, lenvatinib, regorafenib, apatinib, capmatinib, and remtolumab, have been used as an optional therapy for advanced HCC, but the overall efficacy is limited, and drug resistance and side effects are major concerns.
The pathogenesis of HCC is often related to chronic hepatitis and is a complex process with multiple factors and stages of evolution. A single agent or monotherapy regimens could not be expected to solve this problem; thus, the need for combination therapy to achieve synergistic effects is urgent. Angiogenesis and immune evasion are two hallmarks of cancer including HCC. Most HCCs are hypervascular with vascular endothelial growth factor (VEGF) overexpression, which is linked to disease development, metastases, and recurrence. In addition, the VEGF overexpression in hyperactive angiogenesis also contributes to the immunosuppressive microenvironment by affecting multiple immune steps., Since 2013, cytotoxic T-lymphocyte-associated antigen 4, programmed death (PD)-1, and PD-ligand 1 monoclonal antibodies have been applied in HCC, and only 10%–15% of patients were sensitive, and the objective response rate varies.,,, In recent years, the combination of multiple drugs based on immunotherapy and antiangiogenesis has gradually become a new hotspot in the treatment of HCC. The latest report of the combination of atezolizumab and bevacizumab achieved promising clinical efficiency and good patient tolerance and may be approved as a first-line treatment for HCC. The 12-month survival rate of patients with advanced HCC on atezolizumab plus bevacizumab reached 67.2%, breaking the bottleneck in the treatment for more than a decade. Moreover, the combination therapy of apatinib and camrelizumab from China also provided an intriguing clinical effect with the objective response rate and disease control rate being 50.0% and 93.8%. Therefore, TKIs aim to inhibit angiogenesis and normalize blood vessels through regulating molecular pathways, which are crucial for tumor growth and maintenance, whereas immunotherapy endeavors to stimulate a host immune response that effectuates long-lived tumor destruction. In addition, TKIs affect pathways that are also crucial for immune development and function and might optimize antitumor immune responses from immunotherapy. On the other hand, immunotherapy may consolidate the impressive clinical responses from TKIs into long-lasting clinical remissions. Therefore, combined immunotherapy is expected to shift the paradigm as a first-line treatment option for advanced HCC.
In contrast to other types of tumors, where surgery, radiation therapy, and chemotherapy dominate the therapeutic landscape, locoregional treatments including curative and palliative intent (ablations and TACE) are widely applied in HCC. Interestingly, both TACE and ablation (cryotherapy, microwave, or radiofrequency) have been shown to induce local hypoxia, vascular permeability increased, tumor antigen release, T-lymphocyte infiltration and aggregation, and cytokine release or expression.,, However, such responses had been thought to be usually weak and to last for a short time and rarely induce tumor regression. Recently, the results of several preclinical and clinical studies have suggested that locoregional treatments can induce therapeutically effective systemic antiangiogenesis and antitumor immune responses; if appropriate, TKIs and immunotherapies are combined. The preliminary data also suggested a further augmentation of the antitumor effect without overlapping toxicity.,
At present, the greatest challenge of combination therapy lies in how to combine locoregional treatments, TKIs, and immunotherapy for advanced HCC in clinical practice. Recently, a novel “TATI modality” was put forward by Meng et al., which consists of TACE, ablation, TKIs, and immunotherapy applied sequentially in advanced HCC. Four patients underwent TACE treatment at the time of disease diagnosis. During follow-up, the patients were treated with microwave ablation because of a residual tumor or recurrence. For tumor control, apatinib (a TKI drug) was administered after ablation. If the tumor was stable or resistant to TKI, apatinib was continued in combination with immunotherapy (camrelizumab–anti-PD-1 antibody). All four patients had better survival benefits, and the longest survival time of 32 months and the shortest of 17 months achieved with no serious adverse effects. Furthermore, the potential mechanism of TATI modality was also speculated. The results are encouraging and may represent a solution for patients with advanced HCC. This is a very important study and a great contribution to the management of advanced HCC. Certainly, this study met with some limitations. The main limitations were a very preliminary clinical result of case reports and its retrospective nature. Therefore, more prospective, multicenter clinical trials with larger samples are needed to verify the safety and efficacy of the TATI modality.
In the near future, we believe that the novel therapeutic modality would provide a long-term survival and better quality of life for patients with advanced HCC.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al
. Cancer statistics in China, 2015. CA: Cancer J Clin 2016;66:115-32.
Villanueva A. Hepatocellular Carcinoma. New Engl J Med 2019;380:1450-62.
Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al
. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018;6:e555-67.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatology 2018;69:182-236.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al
. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al
. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al
. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al
. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al
. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63.
Ni Y, Ye X. Apatinib for hepatocellular carcinoma. J Cancer Res Ther 2019;15:741-2.
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014;4:522-6.
Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 2015;33:55-63.
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al
. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al
. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al
. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
Li X, Liang P, Ye X. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: “A sharp sword”. J Cancer Res Ther 2019;15:267-8.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al
. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-905.
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al
. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin Cancer Res 2019;25:515-23.
Wang H, Liu Y, Shen K, Dong Y, Sun J, Shu Y, et al
. A comparison between radiofrequency ablation combined with transarterial chemoembolization and surgical resection in hepatic carcinoma: A meta-analysis. J Cancer Res Ther 2019;15:1617-23.
Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, et al
. Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-16.
Takaki H, Cornelis F, Kako Y, Kobayashi K, Kamikonya N, Yamakado K. Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. Diagn Interv Imaging 2017;98:651-9.
Zhou Y, Xu X, Ding J, Jing X, Wang F, Wang Y, et al
. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther 2018;14:40-5.
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015;385:1460-71.
Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, et al
. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94.
Meng M, Li W, Yang X, Huang G, Wei Z, Ni Y, et al
. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. J Cancer Res Ther 2020;16:327-34.